PeptiMatrix Secures £417,500 Angel Investment and Innovate UK Grant to Revolutionize 3D Cell Culture Research

PeptiMatrix, an innovative spinout from the University of Nottingham, is delighted to announce a successful funding round of £417,500, granted by Innovate UK. This infusion of capital represents a significant milestone in our journey as we continue to disrupt traditional methodologies in drug discovery and investigative research. Our cutting-edge peptide hydrogel platform for 3D cell culture is designed to replace reliance on animals and animal-derived products, paving the way for more ethical and efficient research practices. With this grant, we are poised to expand our research capacity and enhance our product offerings, ensuring that laboratories worldwide have access to reliable, scalable, and humane alternatives for cellular studies. The funds will be strategically invested to scale our production capabilities and streamline our manufacturing processes, thereby accelerating the adoption of our platform in various research sectors. At PeptiMatrix, we are committed to revolutionizing how cell cultures are used in drug discovery by providing an innovative solution that not only meets stringent regulatory and ethical standards but also delivers exceptional performance. Our dedicated team of scientists and engineers is working tirelessly to refine our technology and ensure it meets the evolving needs of researchers today. This funding marks a pivotal step forward in our efforts to secure a sustainable future for laboratory research while reducing the ethical concerns associated with animal testing. To learn more about our technology and the exciting opportunities ahead, please visit our website at www.peptimatrix.com.